Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonia that is characterized by a steadily progressive course and poor prognosis. The worsening pulmonary fibrosis resulting in honeycomb lungs accounts for the deterioration of clinical symptoms and functional...
Main Authors: | S. N. Avdeev, N. V. Trushenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2018-10-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2682 |
Similar Items
-
Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023-12-01) -
Idiopathic pulmonary fibrosis: a clinical case of long-term follow-up
by: Galina L. Ignatova, et al.
Published: (2022-09-01) -
Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
by: Yuzo Suzuki, et al.
Published: (2021-07-01) -
Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
by: Yuji Iwanami, et al.
Published: (2022-09-01) -
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
by: James Patrick Finnerty, et al.
Published: (2021-12-01)